TVTX

47.0902.51%
JA

Jeffrey A. Meckler

Independent Director

Mr. Jeffrey A. Meckler, also known as Jeff, JD, served as Co-CEO at Indaptus Therapeutics, Inc. since December 2025 until March 18, 2026 and was Chief Executive Officer since August 2021 until December 2025 and served as Independent Director since February 2021 until March 18, 2026. He was Vice Chairman of Intec Pharma Ltd. since April 9, 2017 until August 2021 and served as its Chief Executive Officer since July 10, 2017 until August 2021. Mr. Meckler had been the Managing Director of The Andra Group since 2009. Mr. Meckler serves as Healthcare Analyst of Ridgeback Capital. He served as the Chief Executive Officer of Cocrystal Pharma, Inc. from October 1, 2015 to July 22, 2016. He joined Ridgeback Capital in 2007. He served as Chief Executive Officer of Trieber Therapeutics from January 2017 to July 2017. He has career in life sciences, as a Consultant to various investors and companies regarding strategy and business development. He served as an Interim Chief Executive Officer of Cocrystal Pharma, Inc. from March 31, 2015 to September 23, 2015. He served as the Principal Executive Officer of QLT Inc. until October 24, 2014. In Pfizer's bid for Warner-Lambert, he became involved with corporate business development. In 2000, he joined Pfizer's Corporate Strategic Planning group and subsequently became part of the Corporate Finance Leadership Team. He was President and Secretary and director of Intec Parent, Inc. from March 2021 until the Merger. From 2000 to 2007, he played a significant role in a number of acquisitions and divestitures. He completed transactions spanned both large deals including Pharmacia, Adams, Vicuron and Esperion as well as smaller deals such as Idun, Rinat, Meridica and Bioren. Mr. Meckler served as an Interim Chief Executive Officer and director of Cypress Bioscience, Inc. from January 2011 to September 2012. He has led a variety of business development activities from large scale acquisitions like Pharmacia to targeted acquisitions such as Meridica and PowderMed. He worked for Bank One (now part of JPMorgan Chase) and Bankers Trust (now part of Deutsche Bank). From 1990 to 2007, he held a series of positions at Pfizer Inc. in Manufacturing Systems, Market Research, Business Development, corporate strategic planning, acquisitions and business development, market research, manufacturing systems, sales operations analysis and Corporate Finance, where he served as an Executive Director of Worldwide Business Development. He served as the Chairman of Travere Therapeutics, Inc. (formerly known as Retrophin, Inc.) until May 18, 2016 and serves as its Independent Director since October 10, 2014. He served an Independent Director of Novelion Therapeutics Inc. (QLT Inc.) from June 4, 2012 to November 29, 2016. Mr. Meckler served as a Director of Cocrystal Pharma, Inc. since April 2015 until July 22, 2016. He served as a Director of Alveolus, Inc. from 2007 to 2009, ClearFarma USA from 2010 to 2012 and Kyalin Bioscience from 2011 to 2012. He served as a Director of NVSS Corp. He served as the President of Children of Bellevue and serves on its Board. He is a Guest Lecturer on issues regarding corporate finance, acquisitions and the healthcare industry at graduate schools such as MIT's Sloan School of Business and The Wharton School of the University of Pennsylvania. He is admitted to the New York Bar. Mr. Meckler earned his B.S. in Industrial Management and his M.S. in Industrial Administration from Tepper School of Business at Carnegie Mellon University. He received his J.D. from Fordham University School of Law.

Positions